rethinkPeptides Search
Menu
Study breakdown

GHRH and GHRP-2 Peptides Override Growth Hormone Feedback Differently in Men and Women

evidence
The takeaway

Combined GHRH and GHRP-2 peptide infusion, sex steroids, and biological sex each independently control how strongly growth hormone suppresses its own release in older adults.

Women's peak GH response > men's (P=0.016)

Dual GHRH/GHRP-2 peptide stimulation produced significantly greater peak GH recovery in postmenopausal women than in older men during controlled feedback conditions

What the researchers found

In a randomized crossover study of 25 healthy older adults, sex differences, sex steroid supplementation (estradiol in women, testosterone in men), and combined GHRH/GHRP-2 peptide infusion each independently and significantly controlled GH autofeedback dynamics. Dual-peptide stimulation elevated nadir GH concentrations independently of sex steroids and sex (P=0.001). Women showed greater peak GH responses to the dual-peptide agonists than men (P=0.016). Sex steroid treatment augmented peak GH recovery during saline infusion (P<0.001). All three factors — sex, sex steroids, and peptide drive — independently augmented peak GH recovery (each P≤0.005).

Why it matters

Growth hormone regulation becomes dysregulated with aging, contributing to changes in body composition, bone density, and metabolism. Understanding how peptide secretagogues (GHRH and GHRP-2) interact with sex steroids and sex differences to control GH pulsatility could inform more effective, personalized GH-axis therapies for age-related hormonal decline.

The numbers in context

n=25 (11 women, 14 men) · dual-peptide nadir GH effect P=0.001 · sex steroid nadir effect P=0.003 · peak GH sex difference P=0.016 · sex steroid peak effect P<0.001 · sex steroid regularity effect P=0.012 · peptide regularity effect P<0.001

How the study worked

Prospective, double-blind, randomized crossover study in 11 postmenopausal women and 14 older men. Each participant received a single IV GH pulse to enforce negative feedback, followed by continuous IV infusion of either saline or combined GHRH/GHRP-2 during pharmacological estradiol (women) or testosterone (men) supplementation versus placebo. Three-way ANCOVA analyzed sex, sex steroid, and peptide effects. Approximate entropy analysis assessed GH regularity.

Who was studied

11 healthy postmenopausal women and 14 healthy older men

What this study cannot tell us

Small sample (25 participants). The pharmacological clamp approach uses supraphysiological conditions that may not reflect normal physiology. Only postmenopausal women and older men were studied, limiting generalizability to younger populations. Short-term study — long-term effects of dual-peptide stimulation were not assessed.

How to read the evidence

Well-designed prospective, double-blind, randomized crossover study in humans with rigorous statistical analysis (three-way ANCOVA, entropy analysis). The crossover design controls for individual variation. However, the small sample size (n=25) and pharmacological conditions limit generalizability.

When this study was published

Published in 2011, this study provides foundational mechanistic data on peptide-driven GH regulation. The GHRH/GHRP-2 combination and sex-specific responses remain relevant to ongoing research in growth hormone secretagogue therapy.

The bigger picture

This study provides mechanistic evidence for why combination peptide therapy (GHRH + GHRP-2) is more effective than single peptides for stimulating GH release, and why responses differ by sex. As growth hormone secretagogue peptides are explored for anti-aging and metabolic health applications, understanding these sex-specific and steroid-dependent responses is essential for optimizing treatment protocols.

Questions still open

  • Could sex-specific dosing of GHRH/GHRP-2 optimize growth hormone therapy outcomes in older adults?
  • Does the greater female response to dual-peptide stimulation persist after accounting for estrogen levels?
  • Would newer GH secretagogue peptides show similar sex-dependent feedback dynamics?

Common questions

What are GHRH and GHRP-2?
GHRH (growth hormone-releasing hormone) is a natural peptide that stimulates GH release from the pituitary gland. GHRP-2 (growth hormone-releasing peptide 2) is a synthetic peptide that stimulates GH through a different receptor (the ghrelin receptor). Together, they activate complementary pathways for a stronger GH response than either alone.
Why did women respond more strongly to the peptide combination?
The study found that biological sex independently influenced GH response to dual-peptide stimulation, with women showing higher peak GH levels than men. This likely reflects sex-based differences in pituitary sensitivity to peptide secretagogues, which may be related to estrogen's known ability to enhance GH release.

Read the original research

Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp.

American journal of physiology. Endocrinology and metabolism, 300(6), E1158-65

Citation

Veldhuis, Johannes D; Erickson, Dana; Miles, John M; Bowers, Cyril Y. (2011). Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp.. American journal of physiology. Endocrinology and metabolism, 300(6), E1158-65. https://doi.org/10.1152/ajpendo.00054.2011